These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy. Marcu LG Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726 [TBL] [Abstract][Full Text] [Related]
7. The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG-0116 and review of future directions. De Los Santos JF; Small W Semin Oncol; 2004 Dec; 31(6 Suppl 18):37-41. PubMed ID: 15726521 [TBL] [Abstract][Full Text] [Related]
8. Future development of amifostine as a radioprotectant. Werner-Wasik M Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272 [TBL] [Abstract][Full Text] [Related]
9. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer. Koukourakis MI Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243 [TBL] [Abstract][Full Text] [Related]
11. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Bourhis J; Rosine D Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247 [TBL] [Abstract][Full Text] [Related]
12. Effect of bryostatin 1 on the in vitro radioprotective capacity of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM). Grant S; Pettit GR; McCrady C Exp Hematol; 1992 Jan; 20(1):34-42. PubMed ID: 1374343 [TBL] [Abstract][Full Text] [Related]
13. Amifostine: the first selective-target and broad-spectrum radioprotector. Kouvaris JR; Kouloulias VE; Vlahos LJ Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063 [TBL] [Abstract][Full Text] [Related]
14. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. Altmann S; Hoffmanns H Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138 [TBL] [Abstract][Full Text] [Related]
15. Radiation-induced toxicities: the role of radioprotectants. Curran WJ Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):2-4. PubMed ID: 9794993 [TBL] [Abstract][Full Text] [Related]
16. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer. Mehta V Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522 [TBL] [Abstract][Full Text] [Related]
17. Potential for use of amifostine in cervical cancer. Small W Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241 [TBL] [Abstract][Full Text] [Related]
19. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Wadler S; Goldberg G; Fields A; Anderson P; Beitler JJ; Sood B; Haynes H; Runowicz C Semin Oncol; 1996 Aug; 23(4 Suppl 8):64-8. PubMed ID: 8783670 [TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]